YM BioSciences has received orphan drug designation from the European Commission for CYT387, a treatment for myelofibrosis, a type of chronic leukemia.
Browsing: ym biosciences
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
The company announced that it has enrolled the first two patients in a clinical trial evaluating nimotuzumab in patients with brain tumors from non-small cell lung cancer (NSCLC).